SCA
AUPH icon

Snowden Capital Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Snowden Capital Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,100
Closed -$70K – 1102
2021
Q4 		$70K Buy
+3,100
New +$73.5K ﹤0.01% 942

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Snowden Capital Advisors's AUPH Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 3,100 shares — an estimated $70K sold.

Snowden Capital Advisors first reported a position in AUPH in Q4 2021 and held it in 1 quarter. The position peaked at $70K in Q4 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 3,100 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $70K.
  • Snowden Capital Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Aurinia Pharmaceuticals position peaked at $70K in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.